

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT5554174

|   |   |
|---|---|
| <b>SUBMISSION TYPE:</b>   | NEW ASSIGNMENT                                |
| <b>NATURE OF CONVEYANCE:</b>  | ASSIGNMENT                                    |
| <b>CONVEYING PARTY DATA</b>   |   |
| <b>Name</b>   | <b>Execution Date</b>                         |
| PROQR THERAPEUTICS II B.V.  | 05/22/2019                                    |
| <b>RECEIVING PARTY DATA</b>   |   |
| <b>Name:</b>  | WINGS THERAPEUTICS, INC.                      |
| <b>Street Address:</b>  | 2600 10TH STREET, #435                        |
| <b>City:</b>  | BERKELEY                                      |
| <b>State/Country:</b>   | CALIFORNIA                                    |
| <b>Postal Code:</b>   | 94710   |
| <b>PROPERTY NUMBERS Total: 2</b>  |   |
| <b>Property Type</b>  | <b>Number</b>                                 |
| <b>Application Number:</b>  | 15554420                                      |
| <b>Application Number:</b>  | 15575559                                      |
| <b>CORRESPONDENCE DATA</b>  |   |
| <b>Fax Number:</b>  | (415)432-6001                                 |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> |   |
| <b>Phone:</b>   | (415) 432-6000                                |
| <b>Email:</b>   | kaheldt@mintz.com                             |
| <b>Correspondent Name:</b>  | WILLIAM B. KEZER                              |
| <b>Address Line 1:</b>  | MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO, PC |
| <b>Address Line 2:</b>  | 44 MONTGOMERY STREET, 36TH FLOOR              |
| <b>Address Line 4:</b>  | SAN FRANCISCO, CALIFORNIA 94104               |
| <b>ATTORNEY DOCKET NUMBER:</b>  | 056520-501N01US-502N01US                      |
| <b>NAME OF SUBMITTER:</b>   | KIMBERLY HELDT                                |
| <b>SIGNATURE:</b>   | /Kimberly Heldt/                              |
| <b>DATE SIGNED:</b>   | 06/04/2019                                    |
| <b>Total Attachments: 8</b>   |   |
| source=Wings Therapeutics - IP Patent Assignment (EXECUTED)#page1.tif   |   |
| source=Wings Therapeutics - IP Patent Assignment (EXECUTED)#page2.tif   |   |
| source=Wings Therapeutics - IP Patent Assignment (EXECUTED)#page3.tif   |   |
| source=Wings Therapeutics - IP Patent Assignment (EXECUTED)#page4.tif   |   |

source=Wings Therapeutics - IP Patent Assignment (EXECUTED)#page5.tif

source=Wings Therapeutics - IP Patent Assignment (EXECUTED)#page6.tif

source=Wings Therapeutics - IP Patent Assignment (EXECUTED)#page7.tif

source=Wings Therapeutics - IP Patent Assignment (EXECUTED)#page8.tif

## DEED OF ASSIGNMENT OF INVENTIONS AND PATENT APPLICATIONS

### Date

This Deed of Assignment is made on .....

### Parties

- (1) **ProQR Therapeutics II B.V.** a Dutch company having its registered office at Zernikedreef 9, 2333 CK Leiden, the Netherlands (the "**Assignor**"); and
- (2) **Wings Therapeutics, Inc.** a company registered in Delaware, USA, and having its registered office at 2600 Tenth Street, #435, Berkeley, CA 94710, the United States of America (the "**Assignee**", which expression includes its successors and assigns);

together the "**Parties**" or each a "**Party**" as the context may indicate.

### Background

- (A) The Assignor is the owner of and is entitled to the benefit of the inventions and the patent applications identified in the Schedule to this Assignment.
- (B) The Assignor has agreed to assign all rights, title and interest in, to and arising from the said inventions and patent applications to the Assignee on the terms set out in this Assignment.

### AGREED TERMS

#### 1. Interpretation

- 1.1 The definitions and rules of interpretation in this clause apply in this Assignment.

"**Inventions**" means the inventions identified by the case numbers and titles listed in the Schedule to this Assignment

"**Patent Applications**" means the patent applications identified by the application numbers and application dates listed in the Schedule to this Assignment and any and all:

- (a) international, national and regional phase applications of all such applications; and
- (b) divisions, continuations and continuations-in-part of all such applications; and
- (c) patents that may be granted pursuant to any of the aforesaid applications for their full period, including any re-issues, re-examinations, renewals, extensions and Supplementary Protection Certificates.

## **2. Assignment**

In consideration of the sum of £1 paid by the Assignee to the Assignor (the receipt and sufficiency of which the Assignor expressly acknowledges), the Assignor hereby assigns to the Assignee, which hereby accepts, all rights, title and interest in Canada, the United States and all other countries of the world in, to and arising from the Inventions and the Patent Applications including (but not limited to):

- (a) in respect of the Inventions and any invention that shall be disclosed in, and all matter that shall be contained in, any of the Patent Applications, the right to file applications, claim priority from such applications, and prosecute and obtain grant of patent or other intellectual property protection in respect of any country, region or territory in the world;
- (b) in respect of each and any of the Patent Applications:
  - (i) the right to claim priority from and to prosecute and obtain grant of patents; and
  - (ii) the right to file divisional applications based on the Patent Applications and to prosecute and obtain grant of patent on each and any such divisional application;
- (c) the right to extend to, or register in or in respect of, any country, region or territory in the world, each and any of the Patent Applications and any patents granted pursuant to any of the Patent Applications;
- (d) the absolute entitlement to any patents granted pursuant to any of the Patent Applications; and
- (e) the right to bring, make, oppose or defend claims or actions, to bring appeal proceedings and to obtain relief (and to retain any damages recovered) in respect of any infringement or any other cause of action arising from ownership of the Inventions or the Patent Applications, whether occurring before on or after the date of this Assignment.

## **3. Issue of Patents**

The Assignor requests the US Commissioner for Patents and the relevant authorities in all countries, regions and territories of the world to issue any patents granted for any of the Inventions or pursuant to any of the Patent Applications in the name of the Assignee in accordance with this Assignment.

## **4. Transfer of titles**

The Assignor authorizes the respective Patent Offices or any governmental agencies to record the Patents and any reissues or re-examinations thereof in the name of the Assignee.

**5. Counterparts**

This Assignment may be executed in any number of counterparts, each of which when executed shall constitute an original of this Assignment, but all the counterparts shall together constitute the same agreement.

**6. Governing law and jurisdiction**

This Assignment shall be governed by and construed in accordance with the internal laws of the State of New York. The Parties agree that the courts of the State of New York shall have exclusive jurisdiction to settle any dispute or claim that arises out of or in connection with this Assignment.

**SCHEDULE: THE INVENTIONS AND THE PATENT APPLICATIONS**

**Case:** 0006  
Title (PCT): Oligonucleotides matching COL7A1 exon 73 for Epidermolysis Bullosa therapy  
Inventor(s): Elisabeth M. Haisma; Marko Potman; Wouter Beumer; Vera Brinks

| <b>ProQR ref</b> | <b>Application No.</b> | <b>Filing date</b> | <b>Publication</b> | <b>Status</b> |
|------------------|------------------------|--------------------|--------------------|---------------|
| 0006 GB 01 PRI   | GB 1504124.7           | 11.03.2015         |                    | Withdrawn     |
| 0006 WO 01 ORD   | PCT/EP2016/055360      | 11.03.2016         | WO 2016/142538     | Expired       |
| 0006 AU 01 PCT   | AU 2016231067          | 11.03.2016         |                    | Pending       |
| 0006 BR 01 PCT   | BR 112017019225-0      | 11.03.2016         | BR 112017019225-0  | Pending       |
| 0006 CA 01 PCT   | CA 2,978,375           | 11.03.2016         |                    | Pending       |
| 0006 CN 01 PCT   | CN 201680015142.2      | 11.03.2016         | CN 107567498 A     | Pending       |
| 0006 EA 01 PCT   | EA 201791986           | 11.03.2016         |                    | Pending       |
| 0006 EP 01 PCT   | EP 16709465.5          | 11.03.2016         | EP 3 268 474       | Pending       |
| 0006 HK 01 PCT   | HK 18101812.4          | 11.03.2016         |                    | Pending       |
| 0006 IL 01 PCT   | IL 254173              | 11.03.2016         |                    | Pending       |
| 0006 IN 01 PCT   | IN 201747035464        | 11.03.2016         |                    | Pending       |
| 0006 JP 01 PCT   | JP 2017-547468         | 11.03.2016         | JP 2018-509903     | Pending       |
| 0006 KR 01 PCT   | KR 10-2017-7025038     | 11.03.2016         |                    | Pending       |
| 0006 MX 01 PCT   | MX/a/2017/011599       | 11.03.2016         | MX/a/2017/011599   | Pending       |
| 0006 NZ 01 PCT   | NZ 736083              | 11.03.2016         |                    | Pending       |
| 0006 US 01 PCT   | US 15/554,420          | 11.03.2016         | US 2018/0216106    | Pending       |
| 0006 ZA 01 PCT   | ZA 2017/05836          | 11.03.2016         |                    | Accepted      |

**Case:** 0008  
Title: Antisense oligonucleotides to treat dystrophic epidermolysis bullosa  
Inventor(s): Elisabeth M. Haisma; Marko Potman; Gerardus J. Platenburg


| <b>ProQR ref</b> | <b>Application No.</b> | <b>Filing date</b> | <b>Publication</b> | <b>Status</b> |
|------------------|------------------------|--------------------|--------------------|---------------|
| 0008 GB 01 PRI   | GB 1508733.1           | 21.05.2015         |                    | Withdrawn     |
| 0008 GB 02 PRI   | GB 1516505.3           | 17.09.2015         |                    | Withdrawn     |
| 0008 WO 01 ORD   | PCT/EP2016/061495      | 20.05.2016         | WO 2016/185041     | Expired       |
| 0008 AU 01 PCT   | AU 2016265457          | 20.05.2016         |                    | Pending       |
| 0008 BR 01 PCT   | BR 112017024800-0      | 20.05.2016         | BR 112017024800-0  | Pending       |
| 0008 CA 01 PCT   | CA 2,986,642           | 20.05.2016         |                    | Pending       |
| 0008 CN 01 PCT   | CN 201680029306.7      | 20.05.2016         | CN 107667174 A     | Pending       |
| 0008 EA 01 PCT   | EA 201792406           | 20.05.2016         |                    | Pending       |
| 0008 EP 01 PCT   | EP 16724048.0          | 20.05.2016         | EP 3 298 144       | Pending       |
| 0008 HK 01 PCT   | HK 18105119.5          | 20.05.2016         |                    | Pending       |
| 0008 IL 01 PCT   | IL 255180              | 20.05.2016         |                    | Pending       |
| 0008 IN 01 PCT   | IN 201747045333        | 20.05.2016         | IN 201747045333    | Pending       |
| 0008 JP 01 PCT   | JP 2017-560600         | 20.05.2016         | JP 2018-515122     | Pending       |
| 0008 KR 01 PCT   | KR 10-2017-7032446     | 20.05.2016         |                    | Pending       |
| 0008 MX 01 PCT   | MX/a/2017/014855       | 20.05.2016         | MX/a/2017/014855   | Pending       |
| 0008 NZ 01 PCT   | NZ 737592              | 20.05.2016         |                    | Pending       |
| 0008 US 01 PCT   | US 15/575,559          | 20.05.2016         | US 2018/0245078    | Allowed       |
| 0008 ZA 01 PCT   | ZA 2017/07133          | 20.05.2016         |                    | Accepted      |

**Case:** 0027  
**Title:** Oligonucleotides for use in the treatment of dystrophic epidermolysis bullosa  
**Owner(s):** ProQR Therapeutics II B.V.  
**Inventor(s):** Jim Swildens, Elisabeth M. Haisma

| <b>ProQR ref</b> | <b>Application No.</b> | <b>Filing date</b> | <b>Publication</b> | <b>Status</b> |
|------------------|------------------------|--------------------|--------------------|---------------|
| 0027 GB 01 PRI   | GB 1902735.8           | 28.02.2019         |                    | Pending       |

Executed as a deed by  
**ProQR Therapeutics II B.V.**

acting by Paul van Dongen,  
General Counsel,



.....  
SIGNATURE OF GENERAL COUNSEL


at (place) .....

on (date) .....

in the presence of:


.....  
NOTARY PUBLIC






SEEN FOR LEGALISATION, by me, Lisanne Bosman (civil law notary) deputising for Joyce Johanna Cornelia Aurelia Leemrijse, civil law notary in Amsterdam, the Netherlands, the signature of Mr Paul van Dongen, born in Tilburg, the Netherlands, on 24 October 1983, holder of a Dutch driving license with number 4528722014, with expiration date 30 May 2022.

Amsterdam, the Netherlands, 22 May 2019.



Executed as a deed by  
**Wings Therapeutics, Inc.**

acting by Mark de Souza,  
President

  
.....  
SIGNATURE OF PRESIDENT

at (place) San Francisco, CA

on (date) 05/22/2019

in the presence of:

  
.....  
NOTARY PUBLIC

